Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of GHRP-6 and IGF-1 (Insulin-like Growth Factor 1) — mechanism, dosing, side effects, legal status, and pricing.
GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) growth hormone secretagogue and ghrelin receptor agonist. Developed by Bowers and Momany and first described in 1984, it was the first synthetic GHRP characterized and is defined by its pronounced appetite-stimulating effect — the strongest of any clinically studied GHRP. It has never been approved by the FDA or any regulatory agency and remains a research-only compound used off-label in the grey market.
Insulin-like Growth Factor 1, a 70-amino-acid peptide hormone that mediates many of growth hormone's anabolic effects. Recombinant IGF-1 (mecasermin) is FDA-approved for severe primary IGF-1 deficiency; non-prescription 'research' use for muscle growth is off-label and unproven.
GHRP-6
IGF-1 (Insulin-like Growth Factor 1)
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
GHRP-6
IGF-1 (Insulin-like Growth Factor 1)
No pricing data yet.
Check IGF-1 (Insulin-like Growth Factor 1) prices →COA corpus from Disclosed Labs — independently tested batches only.
GHRP-6
13
COAs
99.4%
Avg purity
4
Labs
IGF-1 (Insulin-like Growth Factor 1)
1
COAs
—
Avg purity
1
Labs
GHRP-6 is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. IGF-1 (Insulin-like Growth Factor 1) remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
GHRP-6 was first characterized by Bowers, Momany, Reynolds, and Hong in Endocrinology (1984, PMID 6714155), establishing it as the first synthetic peptide to specifically release GH via a non-GHRH mechanism — a key tool in the later discovery of the ghrelin receptor. Ghigo et al. (European Journal of Endocrinology, 1997, PMID 9186261) reviewed the GHRP class and confirmed GH, ACTH/cortisol, and prolactin co-stimulation in humans. Berlanga et al. (Clinical Science, 2007, PMID 16989643) demonstrated ~78% infarct-mass reduction in a porcine myocardial infarction model via antioxidant mechanisms, and Berlanga-Acosta et al. (Clinical Medicine Insights: Cardiology, 2017, PMID 28469491) reviewed the cytoprotective GHRP literature across cardiac, neuronal, and hepatic tissues. GHRP-6 has never been approved for any clinical indication; its intense appetite stimulation and cortisol/prolactin co-release limit its clinical utility compared with ipamorelin.
Key references
Strong endocrinology literature for deficiency states; performance/anti-aging use in healthy adults is not supported by controlled human trials and carries growth-signaling risk.
GHRP-6 and IGF-1 (Insulin-like Growth Factor 1) are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs